Clinical Trials Logo

Glioblastoma (GBM) clinical trials

View clinical trials related to Glioblastoma (GBM).

Filter by:
  • None
  • Page 1

NCT ID: NCT05911230 Recruiting - Glioblastoma (GBM) Clinical Trials

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

AiD-GLIO
Start date: November 24, 2022
Phase: N/A
Study type: Interventional

This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.

NCT ID: NCT05431348 Recruiting - Glioblastoma (GBM) Clinical Trials

Effect of stRess and exeRcize on the Outcome After Chemo-Radiation

ERROR
Start date: June 1, 2022
Phase:
Study type: Observational

Glioblastoma (GBM) is a highly malignant, incurable primary brain tumor. Due to the nature of this disease and the extent of the treatment (surgery followed by chemoradiation according to the Stupp trial) patients undergo considerable psychological distress. It is known that stress hormones are involved in a wide range of processes involved in cell survival, cell cycle and immune function, and can cause therapy resistance. In this study the effect of stress on outcome after chemoradiation in patients with GBM will be investigated.

NCT ID: NCT03867123 Completed - Glioblastoma (GBM) Clinical Trials

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of LAM561 added to first-line treatment for subjects with newly diagnosed glioblastoma (GBM), and to determine the highest safe dose of LAM561 administered orally when added to the concurrent phase of treatment with temozolomide (TMZ) and radiation therapy (RT) or when added to the maintenance phase of treatment with TMZ (once TMZ 200 g/m2/day is started).

NCT ID: NCT02758366 Terminated - Clinical trials for Anaplastic Astrocytoma

Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma

Start date: February 2016
Phase: Phase 2
Study type: Interventional

The standard therapy of glioblastoma (GBM) consists of gross total resection followed by focal irradiation to the tumor bed with concomitant and adjuvant temozolomide (TMZ). The association of valproic acid and TMZ during radiotherapy improves survival of GBM. Preclinical studies suggested that doxorubicin had a strong antineoplastic activity against human gliomas. Moreover, some studies showed that the continuous infusion of anthracyclines in patients with solid tumor ensured a better safety profile compared with bolus administration. Based on these findings, the purpose of this study is to evaluate safety and efficacy of prolonged administration of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in pediatric and adult patients with newly diagnosed GBM and diffuse intrinsic pontine glioma (DIPG).

NCT ID: NCT02046187 Terminated - Glioblastoma (GBM) Clinical Trials

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Start date: October 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to see if reducing blood sugar and increasing ketones (a metabolic product that comes from using fats for energy) can increase survival and enhance the the effects of standard radiation and chemotherapy treatments used to treat glioblastoma multiforme (GBM). These changes occur from use of a ketogenic diet. This research has 2 goals: 1. Show that patients can tolerate the diet and maintain low blood glucose and high blood ketone levels. 2. Show if this diet enhances the effectiveness of standard treatment by prolonging survival of patients with a GBM.